Managing T315I Mutations in CML: Second Line Treatment Options - Ponatinib & Asciminib

Panelists discuss how for patients with chronic myeloid leukemia who develop the T315I mutation, ponatinib and asciminib have demonstrated efficacy in the PACE and ASCEMBL trials, respectively, with ponatinib showing a major cytogenetic response rate in patients with T315I mutation and asciminib demonstrating superior major molecular response vs bosutinib.

EP: 1.Evaluating Early Treatment Response in CML: Expert Insights on Monitoring

EP: 2.Interpreting Milestones: Prioritizing the Patient Picture

Now Viewing

EP: 3.Managing T315I Mutations in CML: Second Line Treatment Options - Ponatinib & Asciminib

EP: 4.Beyond T315I mutations: When to Consider Ponatinib or Asciminib in CML Second-Line Treatment

Video content above is prompted by the following:

• We know that a T315I mutation in the kinase domain confers resistance to our frontline therapies for chronic myeloid leukemia (bosutinib, dasatinib, imatinib, and nilotinib). What therapies are available for patients who develop this mutation while taking their first-line tyrosine kinase inhibitor?
  • Please briefly review the ASCEMBL and PACE trials and key outcomes.

Related Videos